

# Anna Licata

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7364255/publications.pdf>

Version: 2024-02-01

85  
papers

4,040  
citations

159358

30  
h-index

118652

62  
g-index

85  
all docs

85  
docs citations

85  
times ranked

5751  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comorbidities impact and de-prescribing in elderly with HCV-related liver disease: analysis of a prospective cohort. <i>Internal and Emergency Medicine</i> , 2022, 17, 43-51.	1.0	3
2	Efficacy of 8 weeks elbasvir/grazoprevir regimen for naïve-genotype 1b, HCV infected patients with or without glucose abnormalities: Results of the EGG18 study. <i>Digestive and Liver Disease</i> , 2022, 54, 1117-1121.	0.4	1
3	SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3668.	1.8	14
4	Outcome predictors in SARS-CoV-2 disease (COVID-19): The prominent role of IL-6 levels and an IL-6 gene polymorphism in a western Sicilian population. <i>Journal of Infection</i> , 2022, 85, 174-211.	1.7	9
5	Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1190-1199.	1.0	11
6	Liver injury, SARS-CoV-2 infection and COVID-19: What physicians should really know?. <i>GastroHep</i> , 2021, 3, 121-130.	0.3	11
7	The Role of Vitamin Deficiency in Liver Disease: To Supplement or Not Supplement?. <i>Nutrients</i> , 2021, 13, 4014.	1.7	18
8	The Changing Epidemiology of Hepatocellular Carcinoma: Experience of a Single Center. <i>BioMed Research International</i> , 2020, 2020, 1-9.	0.9	15
9	Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort. <i>Antiviral Therapy</i> , 2020, 25, 73-81.	0.6	2
10	Is vitamin D deficiency predictor of complications development in patients with HCV-related cirrhosis?. <i>Internal and Emergency Medicine</i> , 2019, 14, 735-737.	1.0	3
11	Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. <i>Journal of Hepatology</i> , 2019, 71, 265-273.	1.8	138
12	Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? The REAL Experience. <i>American Journal of Gastroenterology</i> , 2019, 114, 1275-1282.	0.2	41
13	Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis. <i>Journal of Hepatology</i> , 2018, 69, 18-24.	1.8	98
14	Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. <i>Gastroenterology</i> , 2018, 155, 411-421.e4.	0.6	291
15	Pancreatic cancer: risk and preventive factors. <i>Internal and Emergency Medicine</i> , 2018, 13, 321-323.	1.0	3
16	Rivaroxaban-induced hepatotoxicity: review of the literature and report of new cases. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 226-232.	0.8	33
17	Letter: effect of HCV eradication on cardiovascular disease—Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1169-1170.	1.9	0
18	Optimizing diagnostic approach to drug-induced liver injury. <i>Italian Journal of Medicine</i> , 2018, 12, 180-189.	0.2	2

#	ARTICLE	IF	CITATIONS
19	Weight-loss supplementation and acute liver failure: the case of Garcinia Cambogia. Internal and Emergency Medicine, 2018, 13, 833-835.	1.0	6
20	Subclinical cardiovascular damage in patients with <scp>HCV</scp> cirrhosis before and after treatment with direct antiviral agents: a prospective study. Alimentary Pharmacology and Therapeutics, 2018, 48, 740-749.	1.9	16
21	Nontumorous Portal Vein Thrombosis in Liver Cirrhosis: Possible Role of $\beta$ -Blockers. Medical Principles and Practice, 2018, 27, 466-471.	1.1	9
22	Copper/MYC/CTR1 interplay: a dangerous relationship in hepatocellular carcinoma. Oncotarget, 2018, 9, 9325-9343.	0.8	30
23	Case report: acute portal vein thrombosis associated with acute cytomegalovirus infection in an immunocompetent adult. Journal of Ultrasound, 2017, 20, 161-165.	0.7	10
24	Inflammation and Aortic Stiffness: An Individual Participant Data Meta-Analysis in Patients With Inflammatory Bowel Disease. Journal of the American Heart Association, 2017, 6, .	1.6	58
25	Characteristics of liver cirrhosis in Italy: Evidence for a decreasing role of HCV aetiology. European Journal of Internal Medicine, 2017, 38, 68-72.	1.0	23
26	Hepatitis delta infection in Italian patients: towards the end of the story?. Infection, 2017, 45, 277-281.	2.3	34
27	Waiting-Time and Quality of Care Deserved to Patients with Early Stage Hepatocellular Carcinoma Undergoing RFA Treatment. Annals of Hepatology, 2017, 16, 699-701.	0.6	1
28	Surveillance Program for Diagnosis of HCC in Liver Cirrhosis: Role of Ultrasound Echo Patterns. BioMed Research International, 2017, 2017, 1-8.	0.9	13
29	A focus on epidemiology of drug-induced liver injury: analysis of a prospective cohort. European Review for Medical and Pharmacological Sciences, 2017, 21, 112-121.	0.5	34
30	Renal function is impaired in normotensive chronic HCV patients: role of insulin resistance. Internal and Emergency Medicine, 2016, 11, 553-559.	1.0	4
31	Cardiac involvement in patients with cirrhosis. Journal of Cardiovascular Medicine, 2016, 17, 26-36.	0.6	12
32	Elderly Onset Celiac Disease: A Narrative Review. Clinical Medicine Insights Gastroenterology, 2016, 9, CGast.S38454.	1.0	28
33	Adverse drug reactions and organ damage: The liver. European Journal of Internal Medicine, 2016, 28, 9-16.	1.0	74
34	Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. Digestive and Liver Disease, 2016, 48, 455-467.	0.4	57
35	Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. Gastroenterology, 2016, 150, 145-155.e4.	0.6	201
36	Sympathovagal balance and 1-h postload plasma glucose in normoglycose tolerant hypertensive patients. Acta Diabetologica, 2016, 53, 41-47.	1.2	3

#	ARTICLE	IF	CITATIONS
37	Insulin-resistance HCV infection-related affects vascular stiffness in normotensives. <i>Atherosclerosis</i> , 2015, 238, 108-112.	0.4	17
38	Clinical course and management of acute and chronic viral hepatitis during pregnancy. <i>Journal of Viral Hepatitis</i> , 2015, 22, 515-523.	1.0	15
39	Non invasive tools for the diagnosis of liver cirrhosis. <i>World Journal of Gastroenterology</i> , 2014, 20, 18131.	1.4	76
40	Considerations regarding the alleged association between Herbalife products and cases of hepatotoxicity: a rebuttal. <i>Internal and Emergency Medicine</i> , 2014, 9, 601-602.	1.0	0
41	Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 1180-1193.	1.9	389
42	Clinical implications of the hyperdynamic syndrome in cirrhosis. <i>European Journal of Internal Medicine</i> , 2014, 25, 795-802.	1.0	48
43	Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: A retrospective cohort study. <i>Digestive and Liver Disease</i> , 2014, 46, 1116-1120.	0.4	44
44	Plasma adiponectin: A contributing factor for cardiac changes in visceral obesity-associated hypertension. <i>Blood Pressure</i> , 2014, 23, 147-153.	0.7	17
45	Liver Function Test Abnormalities in Patients with Inflammatory Bowel Diseases: A Hospital-based Survey. <i>Clinical Medicine Insights Gastroenterology</i> , 2014, 7, CGast.S13125.	1.0	34
46	Herbal hepatotoxicity: a hidden epidemic. <i>Internal and Emergency Medicine</i> , 2013, 8, 13-22.	1.0	61
47	Clinical course and prognostic factors of hepatorenal syndrome: A retrospective single-center cohort study. <i>World Journal of Hepatology</i> , 2013, 5, 685.	0.8	29
48	NT Pro BNP Plasma Level and Atrial Volume Are Linked to the Severity of Liver Cirrhosis. <i>PLoS ONE</i> , 2013, 8, e68364.	1.1	26
49	PNPLA3 GG Genotype and Carotid Atherosclerosis in Patients with Non-Alcoholic Fatty Liver Disease. <i>PLoS ONE</i> , 2013, 8, e74089.	1.1	59
50	Genetic association of interleukin-6 polymorphism (-174 G/C) with chronic liver diseases and hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2013, 19, 2449.	1.4	53
51	Fecal Calprotectin in Clinical Practice. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 504-508.	1.1	29
52	Serology in adults with celiac disease: limited accuracy in patients with mild histological lesions. <i>Internal and Emergency Medicine</i> , 2012, 7, 337-342.	1.0	12
53	Carotid atherosclerosis and chronic hepatitis C: A prospective study of risk associations. <i>Hepatology</i> , 2012, 55, 1317-1323.	3.6	113
54	Fluoroquinolone-induced liver injury: three new cases and a review of the literature. <i>European Journal of Clinical Pharmacology</i> , 2012, 68, 525-532.	0.8	18

#	ARTICLE	IF	CITATIONS
55	Genetic Predisposition to Thrombophilia in Inflammatory Bowel Disease. <i>Journal of Clinical Gastroenterology</i> , 2011, 45, e25-e29.	1.1	4
56	Clinical course and outcomes of drug-induced liver injury: Nimesulide as the first implicated medication. <i>Digestive and Liver Disease</i> , 2010, 42, 143-148.	0.4	30
57	Can chemotherapy concomitantly delivered with radiotherapy improve survival of patients with resectable rectal cancer? A meta-analysis of literature data. <i>Cancer Treatment Reviews</i> , 2010, 36, 539-549.	3.4	37
58	Hyperferritinemia is a risk factor for steatosis in chronic liver disease. <i>World Journal of Gastroenterology</i> , 2009, 15, 2132.	1.4	32
59	Clinical Trial: High-dose furosemide plus small-volume hypertonic saline solutions vs. repeated paracentesis as treatment of refractory ascites. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 227-235.	1.9	20
60	Serum BLYS/BAFF predicts the outcome of acute hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2009, 16, 397-405.	1.0	16
61	Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: A meta-analysis. <i>Journal of Hepatology</i> , 2009, 51, 675-681.	1.8	22
62	Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. <i>Antiviral Therapy</i> , 2009, 14, 631-639.	0.6	22
63	Retinol-binding protein 4: A new marker of virus-induced steatosis in patients infected with hepatitis c virus genotype 1. <i>Hepatology</i> , 2008, 48, 28-37.	3.6	55
64	Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 62-75.	1.9	69
65	Insulin Resistance and Diabetes Increase Fibrosis in the Liver of Patients With Genotype 1 HCV Infection. <i>American Journal of Gastroenterology</i> , 2008, 103, 1136-1144.	0.2	170
66	The impact of radiotherapy on survival in resectable gastric carcinoma: A meta-analysis of literature data. <i>Cancer Treatment Reviews</i> , 2007, 33, 729-740.	3.4	83
67	Oxidative stress inhibits IFN- $\alpha$ -induced antiviral gene expression by blocking the JAK-STAT pathway. <i>Journal of Hepatology</i> , 2006, 45, 271-279.	1.8	83
68	Acute hepatitis C: In search of the optimal approach to cure. <i>Hepatology</i> , 2006, 43, 221-224.	3.6	21
69	Left ventricular filling abnormalities and obesity-associated hypertension: relationship with overproduction of circulating transforming growth factor $\beta$ 1. <i>Journal of Human Hypertension</i> , 2005, 19, 543-550.	1.0	21
70	Treatment of hepatitis C: critical appraisal of the evidence. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 399-408.	0.9	18
71	Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency thermal ablation (RFTA): a prospective study. <i>Journal of Hepatology</i> , 2005, 42, 535-540.	1.8	101
72	Acute polymyositis during treatment of acute hepatitis C with pegylated interferon alpha-2b. <i>Digestive and Liver Disease</i> , 2005, 37, 882-885.	0.4	22

#	ARTICLE	IF	CITATIONS
73	Early carotid atherosclerosis and cardiac diastolic abnormalities in hypertensive subjects. <i>Journal of Human Hypertension</i> , 2004, 18, 201-205.	1.0	30
74	Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. <i>Gut</i> , 2004, 53, 925-930.	6.1	490
75	C4BQ0: a genetic marker of familial HCV-related liver cirrhosis. <i>Digestive and Liver Disease</i> , 2004, 36, 471-477.	0.4	9
76	Expression of Cytokeratin 7 and 20 in Pathological Conditions of the Bile Tract. <i>Pathology Research and Practice</i> , 2003, 199, 65-70.	1.0	22
77	A patient with acute hepatitis C and possible IFN toxicity. <i>Digestive and Liver Disease</i> , 2003, 35, 372-373.	0.4	1
78	Relationship between circulating E-selectin, DD genotype of angiotensin-converting-enzyme, and cardiovascular damage in central obese subjects. <i>Metabolism: Clinical and Experimental</i> , 2003, 52, 999-1004.	1.5	11
79	Expansion of specific $\hat{1}\hat{2}^+$ T-cell subsets in the myocardium of patients with myocarditis and idiopathic dilated cardiomyopathy associated with Coxsackievirus B infection. <i>Human Immunology</i> , 2003, 64, 194-210.	1.2	17
80	IL-10 and TNF- $\hat{1}$ polymorphisms and the recovery from HCV infection. <i>Human Immunology</i> , 2003, 64, 674-680.	1.2	84
81	When and how to treat acute hepatitis C?. <i>Journal of Hepatology</i> , 2003, 39, 1056-1062.	1.8	94
82	Analysis of TCR V $\hat{1}$ Repertoire and Cytokine Gene Expression in Patients with Idiopathic Dilated Cardiomyopathy. <i>Journal of Autoimmunity</i> , 2001, 16, 3-13.	3.0	16
83	Small-Volume Hypertonic Saline Solution and High-Dosage Furosemide in the Treatment of Refractory Congestive Heart Failure. <i>Clinical Drug Investigation</i> , 2000, 19, 9-13.	1.1	11
84	Central obesity and hypertensionThe role of plasma endothelin. <i>American Journal of Hypertension</i> , 1996, 9, 1186-1191.	1.0	56
85	Heredity and obesity-associated hypertension: impact of hormonal characteristics and left ventricular mass. <i>Journal of Hypertension</i> , 1995, 13, 611-618.	0.3	27